Precigen Reports Full Year 2025 Financial Results and Business Updates

Precigen Reports Full Year 2025 Financial Results and Business Updates Accessibility StatementSkip Navigation GERMANTOWN, Md., March 25, 2026 /PRNewswire/ -- Precigen, Inc.(Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced full year 2025 financial results and business updates. "With the FDA approval and launch of PAPZIMEOS, 2025 marked a transformational year for Precigen as we trans ...